



**Written confirmation for active substances exported to the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC**

*Confirmation no. (given by the issuing regulatory authority):* 63B97111

*1. Name and address of site (including building number, where applicable):* EverZinc, 1550 Brouillette, Saint-Hyacinthe, Quebec, J2T 2G8, Canada

*2. Manufacturer's licence number(s):*<sup>1</sup> 3-002638-A

REGARDING THE MANUFACTURING PLANT UNDER (1) OF THE FOLLOWING ACTIVE SUBSTANCE(S) EXPORTED TO THE EU FOR MEDICINAL PRODUCTS FOR HUMAN USE

Active substance(s): <sup>2</sup>	Activity(ies): <sup>3</sup>
Zinc Oxide USP	Transformation of zinc to zinc oxide by pyrometallurgical process (french process)

Terms & Conditions: Only manufacturing line #2 & line #5 are allowed to be used for the manufacturing operations of Zinc Oxide (USP).

THE ISSUING REGULATORY AUTHORITY HEREBY CONFIRMS THAT:

The standards of good manufacturing practice (GMP) applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.<sup>4</sup>

*Date of inspection of the plant under (1): Name of inspecting authority if different from the issuing regulatory authority:*

- Health Canada inspected the facility on December 7-10th, 2021.

<sup>1</sup> Where the regulatory authority issues a licence for the site. Record 'not applicable' in case where there is no legal framework for issuing of a licence.

<sup>2</sup> Identification of the specific active substances through an internationally-agreed terminology (preferably international nonproprietary name).

<sup>3</sup> For example, 'Chemical synthesis', 'Extraction from natural sources', 'Biological processes', 'Finishing steps'.

<sup>4</sup> qdefect@ema.europa.eu.



Health Canada Santé Canada

This written confirmation remains valid until December 7th, 2023.

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

*Address of the issuing regulatory authority:*

Jeanne Mance Building, 13th Floor, 200 Eglantine Driveway, Address Locator #1913-A, Ottawa, Ontario, Canada, K1A 0K9

*Name and function of responsible person:*

Kim Godard, Director, Health Product Inspection and Licensing, Health Canada

*E-mail, Telephone no.:*

[kim.godard@canada.ca](mailto:kim.godard@canada.ca)

Tel. no.: 613-404-7882

*Signature*

*Date*

February 25<sup>th</sup>, 2022

X

---

.....